09-26-2017 01:00 PM CET - Health & Medicine
Print

First patient in Malaysia successfully treated with Urolastic™ - collaboration between Leader Biomedical and Urogyn yields first results

Press release from: Leader Biomedical

Urogyn B.V. and Leader Biomedical announce the first patient treated in Malaysia with Urolastic™– an innovative Urinary Stress Incontinence product that is exclusively offered by Leader Biomedical in India and APAC.
We are excited to announce that we have successfully introduced Urolastic™ in Malaysia and treated a female patient suffering from severe Stress Urinary Incontinence (SUI). The patient suffered from the condition, as a result of birth deficiencies and was diagnosed with a short, yet very wide urethra. After previously undergoing a procedure using a bulking agent, the patient went down from using eight pads a day, to five pads a day. Treatment with Urolastic™ earlier this month by Dr. Warren Lo Hwa Loon at Pantai Hospital Kuala Lumpur has improved the patient’s condition, as a result of which she now only uses one pad a day, thus significantly improving her quality of life.

Stress Urinary Incontinence is a disease affecting over 200 million people worldwide. Traditionally, SUI is treated with either a sling or injection of a bulking agent, where a sling procedure is an invasive procedure for the patient and the traditional bulking agents are expensive, as they are only effective for a short period and need to be repeated regularly.

“Patients who would benefit from bulking agent procedure are those that suffered from a failed sling procedure, elderly patients that are happy with a positive effect and incontinence reduction rather than a guaranteed total stop of leakage, and patients that prefer minimally-invasive surgery as opposed to sling procedure surgery” shares Dr. Warren Lo Hwa Loon, Pantai Hospital Kuala Lumpur.
“Urolastic™ is the most effective bulking agent available to patients suffering from SUI. The agent stays at the application site since it is not a fluid in the body, but hardens to form a solid mass. Also, treatment with Urolastic™ is an outpatient procedure in most cases. In addition to being an attractive procedure for the elderly and after failed sling procedures, it also provides an alternative for women who still wish to have children”, adds Dr. Pieter Venema, urologist and experienced Urogyn trainer from the Netherlands.

Urolastic™ is an extremely biocompatible rubbery compound that forms in place after injection. The mixture forms as small flexible beads, which are over time encapsulated in scar tissue. Urolastic™ is injectable and does not shrink or degrade, thus remains effective in the longer term. The material also shows on X-rays and ultrasound and can be removed if required.
Following the earlier communications on Urolastic™ this is a promising step towards offering a minimally-invasive, outpatient, long-lasting treatment of women suffering from SUI.

About Urogyn: Urogyn was founded in 2009 with the ambition of developing new products in the field of urology and gynaecology, based upon a two-component polymer technology. The first products are now used in the treatment of Stress Urinary Incontinence (SUI) for both men and women. More products are expected to be commercially launched in the near future for birth control and treating faecal incontinence (www.urogynbv.com).

About Leader Biomedical: Leader Biomedical is committed to improving global access to innovative biomaterials and implantable medical devices and extending the reach of patients and caregivers by developing new technologies, delivering world class contract manufacturing services, and providing healthcare solutions. Leader Biomedical offers a wide range of therapeutic solutions, focusing on orthopaedic, dental, wound care and sports medicine. Our orthopaedic products can be used in both surgical and non-surgical procedures related to treating conditions ranging from musculoskeletal trauma, infections, malignancies, congenital disorders, reconstructive dental surgery, and sports injuries (www.leaderbiomedical.com).

Herikerbergweg 300, Diana Building
1101 CT Amsterdam
The Netherlands

This release was published on openPR.
News-ID: 738521 • Views: 334
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: